Inhibrx Inc (INBX)

$34.11

-0.24

(-0.7%)

Market is closed - opens 7 PM, 30 May 2024

Insights on Inhibrx Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 17.0K → 1.63M (in $), with an average increase of 70.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -93.60M → -78.71M (in $), with an average increase of 18.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 66.0% return, outperforming this stock by 20.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 236.3% return, outperforming this stock by 175.1%

Performance

  • $34.09
    $34.49
    $34.11
    downward going graph

    0.06%

    Downside

    Day's Volatility :1.16%

    Upside

    1.1%

    downward going graph
  • $14.31
    $39.79
    $34.11
    downward going graph

    58.05%

    Downside

    52 Weeks Volatility :64.04%

    Upside

    14.27%

    downward going graph

Returns

PeriodInhibrx IncSector (Health Care)Index (Russel 2000)
3 Months
-6.88%
-2.3%
0.0%
6 Months
64.23%
7.8%
0.0%
1 Year
45.09%
11.7%
0.0%
3 Years
54.34%
14.5%
-22.0%

Highlights

Market Capitalization
1.8B
Book Value
$0.24
Earnings Per Share (EPS)
-5.48
Wall Street Target Price
35.5
Profit Margin
0.0%
Operating Margin TTM
-13980.93%
Return On Assets TTM
-57.46%
Return On Equity TTM
-2031.05%
Revenue TTM
1.8M
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
496.40000000000003%
Gross Profit TTM
-108.0M
EBITDA
-248.0M
Diluted Eps TTM
-5.48
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.86
EPS Estimate Next Year
-6.17
EPS Estimate Current Quarter
-1.04
EPS Estimate Next Quarter
-1.05

Analyst Recommendation

Hold
    0
    0%Buy
    62%Hold
    37%Sell
Based on 8 Wall street analysts offering stock ratings for Inhibrx Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
6
Hold
5
5
3
Sell
3
3
00

Analyst Forecast

What analysts predicted

Upside of 4.08%

Current $34.11
Target $35.50

Technicals Summary

Sell

Neutral

Buy

Inhibrx Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inhibrx Inc
Inhibrx Inc
0.21%
64.23%
45.09%
54.34%
65.34%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
12.3%
24.33%
35.61%
110.39%
159.09%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
8.51%
17.32%
32.65%
92.06%
213.84%
Moderna, Inc.
Moderna, Inc.
34.09%
90.37%
17.56%
-19.9%
588.32%
Novo Nordisk A/s
Novo Nordisk A/s
3.41%
30.28%
66.05%
235.09%
462.44%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inhibrx Inc
Inhibrx Inc
NA
NA
NA
-5.86
-20.31
-0.57
NA
0.24
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.67
29.67
0.53
17.14
0.24
0.13
NA
71.8
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.07
29.07
1.46
44.13
0.15
0.08
NA
250.15
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Novo Nordisk A/s
Novo Nordisk A/s
47.21
47.21
2.36
3.51
1.0
0.25
0.01
22.18
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inhibrx Inc
Inhibrx Inc
Hold
$1.8B
65.34%
NA
0.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.3B
159.09%
29.67
39.46%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.2B
213.84%
29.07
29.45%
Moderna, Inc.
Moderna, Inc.
Buy
$56.7B
588.32%
24.73
-115.82%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$597.3B
462.44%
47.21
36.55%

Institutional Holdings

  • Viking Global Investors LP

    13.65%
  • RA Capital Management, LLC

    9.02%
  • Perceptive Advisors LLC

    8.12%
  • BlackRock Inc

    5.18%
  • Vanguard Group Inc

    3.55%
  • TCG Crossover Management, LLC

    3.34%

Company Information

development of antibodies

Organization
Inhibrx Inc
Employees
166
CEO
Mr. Mark Paul Lappe
Industry
Health Technology

FAQs